Evidence map›Paper›PMID 34552325›Full record

ArticleInternational journal of chronic obstructive pulmonary disease

Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England.

Leah B Sansbury, Kieran J Rothnie, Chanchal Bains, Chris Compton, Glenn Anley, Afisi S Ismaila

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Leah B SansburyValue Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, Durham, NC, USA.
Kieran J RothnieValue and Evidence Outcomes, GlaxoSmithKline, Uxbridge, UK.
Chanchal BainsReal World Evidence and Epidemiology, GlaxoSmithKline, Uxbridge, UK.
Chris ComptonGlobal Respiratory Franchise, GlaxoSmithKline, Brentford, UK.
Glenn AnleyValue and Evidence Outcomes, GlaxoSmithKline, Uxbridge, UK.
Afisi S IsmailaValue Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA.ORCID 0000-0002-2876-8308

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAvailable data on the relationship between COPD symptoms, disease outcomes, and mortality are currently limited. This study investigated the clinical characteristics, outcomes, healthcare utilization, and prescribing practices across GOLD 2017 groups (A, B, C, and D) in a large-scale, population-based cohort of COPD patients managed in an English primary care setting. PATIENTS AND

methodsThis retrospective analysis included patients aged ≥35 years, with a confirmed diagnosis of COPD and ≥1 record of pulmonary function testing in their medical history. Medical Research Council dyspnea score and exacerbation history were used to define patients' GOLD 2017 classification. Patients were identified using the UK Clinical Practice Research Database and were followed for 12 months.

resultsEligible COPD patients' (N=42,331; mean [SD] age, 69.5 [10.7] years; 54% males), GOLD 2017 categorizations were: Group A: 49.1%, Group B: 30.5%, Group C: 8.2%, Group D: 12.1%. Overall, 37.7% of patients experienced ≥1 moderate COPD exacerbation. The rate of moderate exacerbations per person per year (PPPY) was highest in GOLD group D (0.72), followed by C (0.53), B (0.22), and A (0.15), while the rate of exacerbations leading to hospitalization PPPY was much higher in D (0.27) than in B (0.10), C (0.08), or A (0.03). Overall, 56.4% of patients visited their general practitioner ≥5 times in the 12 months of follow-up. Time-to-event analysis suggested that breathlessness contributed to exacerbation severity and frequency. One-year mortality was highest in GOLD groups D and B. The most frequent prescribed maintenance therapies were inhaled corticosteroids with long-acting β

conclusionThe burden of COPD remains substantial in England. Stratification of this large primary care population according to GOLD criteria predicted the risk of COPD exacerbations. Understanding populations of patients with COPD may enable the optimization of patient care.

Indexed as

Pulmonary Disease, Chronic ObstructiveAdrenal Cortex HormonesAgedAged, 80 and overBronchodilator AgentsDelivery of Health CareDisease ProgressionEnglandFemaleHumansMaleMiddle AgedMuscarinic AntagonistsRetrospective StudiesAdrenal Cortex HormonesBronchodilator AgentsMuscarinic Antagonistschronic obstructive lung diseasedatabaseexacerbationsGlobal Initiative for Chronic Obstructive Lung Diseasehealthcare costsmaintenance therapy

Identifiers

PMID34552325
PMCPMC8450675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.